$INO News
Last published 17h ago
- 17h agoINOINOVIO to Participate in Upcoming Investor ConferencesPR NewswireINOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from...
- 1d agoINOINOVIO 3rd Quarter 2026 Financial Results Conference Call - INOVIO PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals 3rd Quarter 2026 Financial Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will con
- 1d agoINOINOVIO PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoINOINOVIO Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPR NewswireVOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the...
- 6d agoINOINOVIO Announces Pricing of Approximately $75 Million Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
- 1w agoINOVOCERYQ FDA Accelerated Approval - INOVIO Investor Call - INOVIO PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Vosarik FTA Accelerated Approval Univio Investor Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a qu
- 1w agoINOINOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)PR NewswireINOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgeryVOCERYQ™ is a plasmid DNA-based immunotherapy that
- 3w agoINOINOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life SciencePR NewswirePLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people
- 2mo agoINOINOVIO to Participate in Upcoming Investor ConferencesPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 3mo agoINOINOVIO Second Quarter 2026 Financial Results Conference Call - INOVIO PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, ladies and gentlemen, and welcome to the Inovio Second Quarter 2026 Financial Assaults Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a que
- 3mo agoINOINOVIO Reports Second Quarter 2026 Financial Results and Recent Business HighlightsPR NewswireU.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act
- 3mo agoINOINOVIO to Report Second Quarter Financial Results on August 12, 2026PR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 3mo agoINOINOVIO Announces Pricing of $20.0 Million Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
- 3mo agoINOINOVIO Announces Proposed Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
- 5mo agoINOKuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ:...
- 5mo agoINOKuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireNEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) breached their
- 5mo agoINOINOVIO to Participate in Upcoming Scientific and Investor ConferencesPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 5mo agoINOPositive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in ChinaPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 6mo agoINOINOVIO Reports First Quarter 2026 Financial Results and Recent Business HighlightsPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 6mo agoMRNAINONVAXEBSHantavirus cases spark surge in pharma and biotech stocks — here’s whyCNBCThe outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.
- 6mo agoINOINOVIO to Participate in Upcoming Scientific ConferencesPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 6mo agoINOINOVIO to Report First Quarter Financial Results on May 13, 2026PR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 7mo agoINOINOVIO Announces Pricing of $17.5 Million Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
- 7mo agoINOINOVIO Announces Proposed Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
- 7mo agoINOINOVIO to Participate in Upcoming Scientific ConferencePR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 8mo agoINOINOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 8mo agoINOInovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INOPR NewswireThe Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of...
- 8mo agoINOINOVIO to Participate in Upcoming Scientific ConferencesPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 8mo agoINOInovio Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – INOGlobeNewswireNEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ:INO). Shareholders who purchased shares of INO during the class
- 8mo agoINOINOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026PR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 8mo agoINOAkeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)PR NewswireAkeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply...
- 8mo agoINOINOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)PR NewswireINOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply...
- 8mo agoINOInvestors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INOPR NewswireThe Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of...
- 9mo agoINOINOVIO to Participate in Upcoming Scientific and Investor ConferencesPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 10mo agoINOFDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)PR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 10mo agoINOINOVIO Reports Inducement Grant Under Inducement PlanPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 11mo agoINOINOVIO to Participate in December Investor ConferencesPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO Announces Pricing of $25 Million Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
- 1y agoINOINOVIO Announces Proposed Public OfferingPR NewswireINOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
- 1y agoINOINOVIO Reports Third Quarter 2025 Financial Results and Recent Business HighlightsPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in AdultsPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO Reports Inducement Grant Under Inducement PlanPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025PR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat ConferencePR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOClinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature MedicinePR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO Reports Inducement Grant Under Inducement PlanPR NewswireINOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOINOVIO to Participate in Upcoming Scientific ConferencesPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
- 1y agoINOInovio Pharmaceuticals, Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 1y agoINOInovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)Earnings Call Transcripts
- 1y agoINOINOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in AdultsPR NewswireINOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...